Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Anti-Retroviral Agents*/administration & dosage ; Anti-Retroviral Agents*/economics ; HIV Infections*/drug therapy ; HIV Infections*/economics ; HIV Infections*/epidemiology ; Hospitalization* ; Quality of Life*; Adolescent ; Adult ; Costs and Cost Analysis ; Female ; Humans ; Malawi/epidemiology ; Male ; Middle Aged ; Prevalence ; Prospective Studies

Introduction: Although HIV infection and its associated co-morbidities remain the commonest reason for hospitalisation in Africa, their impact on economic costs and health-related quality of life (HRQoL) are not well understood. This information is essential for decision-makers to make informed choices about how to best scale-up anti-retroviral treatment (ART) programmes. This study aimed to quantify the impact of HIV infection and ART on economic outcomes in a prospective cohort of hospitalised patients with high HIV prevalence.
Methods: Sequential medical admissions to Queen Elizabeth Central Hospital, Malawi, between June-December 2014 were followed until discharge, with standardised classification of medical diagnosis and estimation of healthcare resources used. Primary costing studies estimated total health provider cost by medical diagnosis. Participants were interviewed to establish direct non-medical and indirect costs. Costs were adjusted to 2014 US$ and INT$. HRQoL was measured using the EuroQol EQ-5D. Multivariable analyses estimated predictors of economic outcomes.
Results: Of 892 eligible participants, 80.4% (647/892) were recruited and medical notes found. In total, 447/647 (69.1%) participants were HIV-positive, 339/447 (75.8%) were on ART prior to admission, and 134/647 (20.7%) died in hospital. Mean duration of admission for HIV-positive participants not on ART and HIV-positive participants on ART was 15.0 days (95%CI: 12.0-18.0) and 12.2 days (95%CI: 10.8-13.7) respectively, compared to 10.8 days (95%CI: 8.8-12.8) for HIV-negative participants. Mean total provider cost per hospital admission was US$74.78 (bootstrap 95%CI: US$25.41-US$124.15) higher for HIV-positive than HIV-negative participants. Amongst HIV-positive participants, the mean total provider cost was US$106.87 (bootstrap 95%CI: US$25.09-US$106.87) lower for those on ART than for those not on ART. The mean total direct non-medical and indirect cost per hospital admission was US$87.84. EQ-5D utility scores were lower amongst HIV-positive participants, but not significantly different between those on and not on ART.
Conclusions: HIV-related hospital care poses substantial financial burdens on health systems and patients; however, per-admission costs are substantially lower for those already initiated onto ART prior to admission. These potential cost savings could offset some of the additional resources needed to provide universal access to ART.

AIDS Care. 2009 Nov;21(11):1343-56. (PMID: 20024710)
Curr Opin HIV AIDS. 2010 May;5(3):215-24. (PMID: 20539077)
BMJ. 2000 Apr 29;320(7243):1197-200. (PMID: 10784550)
Lancet. 2008 Mar 1;371(9614):752-9. (PMID: 18313504)
BMC Pulm Med. 2012 Aug 30;12:46. (PMID: 22935579)
PLoS One. 2014 Nov 12;9(11):e108304. (PMID: 25389777)
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):211-7. (PMID: 21546850)
PLoS One. 2010 Dec 30;5(12):e15677. (PMID: 21209893)
Lancet. 2009 Sep 19;374(9694):1023-1031. (PMID: 19709737)
BMJ. 2005 Nov 12;331(7525):1137-40. (PMID: 16282411)
Lancet Infect Dis. 2015 May;15(5):544-51. (PMID: 25765217)
Med Care. 1997 Nov;35(11):1095-108. (PMID: 9366889)
Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S29-37. (PMID: 12971652)
Qual Life Res. 2000;9(8):901-10. (PMID: 11284209)
J Health Econ. 2001 Jul;20(4):461-94. (PMID: 11469231)
Popul Health Metr. 2003 Dec 16;1(1):11. (PMID: 14678566)
Int J Tuberc Lung Dis. 2013 Sep;17(9):1125-38. (PMID: 23928165)
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):322-328. (PMID: 23187948)
J Health Serv Res Policy. 2004 Oct;9(4):197-204. (PMID: 15509405)
PLoS Med. 2006 Jan;3(1):e4. (PMID: 16318413)
N Engl J Med. 2011 Oct 20;365(16):1482-91. (PMID: 22010914)
PLoS One. 2016 Feb 17;11(2):e0148546. (PMID: 26885977)
Health Qual Life Outcomes. 2012 Feb 03;10:20. (PMID: 22304795)
PLoS Med. 2013;10(3):e1001400. (PMID: 23554578)
Health Econ. 1996 Mar-Apr;5(2):141-54. (PMID: 8733106)
Demography. 2001 Feb;38(1):115-32. (PMID: 11227840)
Trans R Soc Trop Med Hyg. 2003 Jan-Feb;97(1):91-6. (PMID: 12886812)
J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):410-6. (PMID: 17786130)
Int Health. 2013 Mar;5(1):58-63. (PMID: 24029847)
Cost Eff Resour Alloc. 2010 Apr 16;8:5. (PMID: 20398367)
BMC Med. 2016 Feb 19;14:34. (PMID: 26891969)
Lancet. 2009 Apr 18;373(9672):1352-63. (PMID: 19361855)
BMC Infect Dis. 2009 Dec 15;9:205. (PMID: 20003472)

United Kingdom Wellcome Trust; G0501681 United Kingdom MRC_ Medical Research Council; G0700452 United Kingdom MRC_ Medical Research Council

0 (Anti-Retroviral Agents)

Date Created: 20180316 Date Completed: 20180618 Latest Revision: 20240314

20240314

PMC5854246

10.1371/journal.pone.0192991

29543818